Rocket


News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Immunocore Holdings plc (IMCR) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Unaudited Condensed Consolidated Interim Financial Statements as at and for the Three and Six Months Ended June 30, 2023",
"Management’s Discussion and Analysis of Financial Condition and Results of Operations as at and for the Three and Six Months Ended June 30, 2023",
"Bahija Jallal, Chief Executive Officer of Immunocore",
"2Q 2023 1H 2023 KIMMTRAK"
07/14/2023 6-K Quarterly results
05/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Unaudited Condensed Consolidated Interim Financial Statements as at and for the Three Months Ended March 31, 2023",
"Management’s Discussion and Analysis of Financial Condition and Results of Operations as at and for the Three Months Ended March 31, 2023",
"Ralph Torbay, Head of Commercial of Immunocore"
04/18/2023 6-K Quarterly results
04/18/2023 6-K Quarterly results
03/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
03/02/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Company letter to the shareholders",
"Company letter to the shareholders"
03/01/2023 6-K Quarterly results
02/22/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"David Berman, Head of R&D of Immunocore",
"Slides Added to Corporate Presentation"
01/11/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Annual J.P. Morgan Healthcare Conference presentation",
"Annual J.P. Morgan Healthcare Conference presentation"
01/09/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Cytokine Release Syndrome , which may be serious or life-threatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated. Manifestations of CRS may include fever, hypotension, hypoxia, chills, nausea, vomiting, rash, elevated transaminases, fatigue, and headache. CRS occurred in 89% of patients who received KIMMTRAK with 0.8% being grade 3 or 4. Ensure immediate access to medications and resuscitative equipment to manage CRS. Ensure patients are euvolemic prior to initiating the infusions. Closely monitor patients for signs or symptoms of CRS following infusions of KIMMTRAK. Monitor fluid status, vital signs, and oxygenation level and provide appropriate therapy. Withhold or discontinue KIMMTRAK depending ...",
"Corporate Presentation",
"Pipeline Chart"
12/08/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Immunocore presents ovarian cancer expansion data for ImmTAC ® candidate IMC-C103C targeting MAGE-A4"
12/02/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta TCR ImmTAC for Solid Tumors"
11/09/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Unaudited Condensed Consolidated Interim Financial Statements for the Three and Nine Months Ended September 30, 2022",
"Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Three and Nine Months Ended September 30, 2022",
"commented Bahija Jallal, Chief Executive Officer of Immunocore.",
"Loan agreement, among Immunocore Limited, as Borrower, the Registrant, certain additional Credit Parties and Guarantors party thereto, BioPharma Credit PLC, as Collateral Agent, and BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP as Lenders"
09/30/2022 6-K Quarterly results
09/09/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Sales Agreement, by and between the Company and Jefferies LLC",
"Opinion of Cooley (UK) LLP",
"Recent Developments section of the Prospectus Supplement Summary included in the Company’s Prospectus Supplement to the Registration Statement on Form F-3ASR (File No. 333-264105)"
09/09/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress",
"Investor and Analyst Presentation"
08/10/2022 6-K Quarterly results
07/20/2022 6-K Quarterly results
07/11/2022 6-K Quarterly results
06/27/2022 6-K Quarterly results
06/09/2022 6-K Quarterly results
06/08/2022 6-K Quarterly results
06/06/2022 6-K Quarterly results
06/03/2022 6-K Quarterly results
05/12/2022 6-K Quarterly results
05/11/2022 6-K Quarterly results
04/14/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Notice of Annual General Meeting",
"Form of Proxy",
"Depositary’s Notice of Annual General Meeting",
"American Depositary Share Voting Instruction Card"
04/04/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Dr. Jessica Hassel, Head of Dermatooncology at Heidelberg University Hospital, said “The approval of tebentafusp by the EMA is a great step forward in the treatment of metastatic uveal melanoma. Being the first agent with a proven survival benefit, this approval provides hope to patients with uveal melanoma. And for us treating physicians, it is a significant advancement to be able to offer these patients an effective treatment with good tolerability.” With EC approval, KIMMTRAK has received marketing authorisation in all E.U. member states, and following completion of related national procedures, also in Iceland, Liechtenstein, and Norway. The United Kingdom’s Medicines and Healthcare Regulatory Agency , Health Canada, and the Australian Government Department of Health Therapeutic Goods A..."
03/03/2022 6-K Quarterly results
01/26/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Bahija Jallal, Chief Executive Officer of Immunocore, said: “Today’s approval of KIMMTRAK is a historic milestone and the culmination of years of dedication by the Immunocore team, patients, and our healthcare partners. Every year in the United States, hundreds of people are diagnosed with metastatic uveal melanoma who, until now, had no approved treatment options. KIMMTRAK is the first therapy to demonstrate a survival benefit to patients with this disease and we are focused on making KIMMTRAK available as quickly as possible."
12/07/2021 6-K Quarterly results
11/10/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Unaudited Condensed Consolidated Interim Financial Statements for the Three and Nine Months Ended September 30, 2021",
"Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Three and Nine Months Ended September 30, 2021",
"Bahija Jallal, Chief Executive Officer of Immunocore, said: “We continue to be encouraged by the interest in our tebentafusp data in metastatic uveal melanoma, including the publication of our Phase 3 data in the New England Journal of Medicine. We have now activated our early access program in fourteen countries and have treated over 150 patients with metastatic uveal melanoma over the last six months. As we advance our ImmTAC programs in other solid tumors, we look forward to continuing to update on our progress at upcoming medical meetings.” Third Quarter 2021 Highlights"
08/24/2021 6-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy